Relationship Between <i>ERCC1</i> Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer

200872 citationsJournal Article

Authors

Thomas C. Krivak · Roswell Park Comprehensive Cancer Center

Kathleen M. Darcy · Sidney Kimmel Cancer Center

Chunqiao Tian · Gynecologic Oncology Group

Deborah K. Armstrong · Magee-Womens Hospital

Bora Baysal · Precision Therapeutics (United States)

Holly H. Gallion · Gynecologic Oncology Group

Christine B. Ambrosone

Abstract

Although the ERCC1 codon 118 polymorphism does not seem to be associated with clinical outcome, the C8092A polymorphism was an independent predictor of PFS and OS in women with optimally resected EOC.

Topics & Keywords

Ovarian cancer diagnosis and treatment Endometrial and Cervical Cancer Treatments Intraperitoneal and Appendiceal Malignancies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 26, Issue 21, pp. 3598-3606

DOI: 10.1200/jco.2008.16.1323

Field-Weighted Citation Impact: 10.87